Pancreatic Cancer Research

ResearcherNational Cancer CenterActive in the last 2 years

Woo Jin Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2115-6701; OpenAlex author ID A5100410784. Sources: OpenAlex.

Their work

Papers
43 (first author 4, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
121
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 4 papers · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 5 papers · 2019: 4 papers · 2020: 3 papers · 2021: 3 papers · 2022: 1 paper · 2023: 4 papers · 2024: 4 papers · 2025: 6 papers · 2026: 3 papers

Papers 43

  1. Impact of treatment sequence and dose response on outcomes in locally advanced pancreatic cancer treated with hypofractionated proton beam therapy using simult… Last author DOI 10.1016/j.radonc.2025.111295↗
  2. Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-4517↗
  3. Prognostic Value and Longitudinal Dynamics of Multigene Circulating Tumor DNA in Advanced Pancreatic Cancer Treated with 5-Fluorouracil-Based Chemotherapy. Co-author DOI 10.3390/ijms27198668↗
  4. ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167625↗
  5. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Co-author DOI 10.1093/clinchem/hvaf066↗
  6. Effectiveness and cost analysis of liposomal irinotecan in patients with pancreatic adenocarcinoma: a multicenter real-world study. Co-author DOI 10.1177/17588359251370492↗
  7. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  8. Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospective Cohort Study. Co-author DOI 10.3390/cancers17050896↗
  9. Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. Co-author DOI 10.3390/cancers17182988↗
  10. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin leve… Co-author DOI 10.1038/s41416-023-02474-w↗
  11. Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum … Co-author DOI 10.1038/s41416-023-02520-7↗
  12. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Co-author DOI 10.1111/cas.16104↗
  13. The Impact of the Dietary Inflammatory Index, Fasting Blood Glucose, and Smoking Status on the Incidence and Survival of Pancreatic Cancer: A Retrospective Cas… Co-author DOI 10.3390/nu16223941↗
  14. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  15. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  16. Exploring Connections between Oral Microbiota, Short-Chain Fatty Acids, and Specific Cancer Types: A Study of Oral Cancer, Head and Neck Cancer, Pancreatic Can… Co-author DOI 10.3390/cancers15112898↗
  17. Annotation-Efficient Deep Learning Model for Pancreatic Cancer Diagnosis and Classification Using CT Images: A Retrospective Diagnostic Study. Co-author DOI 10.3390/cancers15133392↗
  18. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic a… Co-author DOI 10.1177/17588359221119539↗
  19. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. Co-author DOI 10.3390/cancers13215466↗
  20. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.3.144↗
  21. CORRIGENDUM: Addition of data source: Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.4.252↗
  22. Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. First author DOI 10.1038/s41598-020-78875-1↗
  23. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. Co-author DOI 10.1097/coc.0000000000000730↗
  24. Multi-Biomarker Panel Prediction Model for Diagnosis of Pancreatic Cancer: a retrospective and multi-center cohort study Co-author DOI 10.21203/rs.3.rs-76136/v1↗
  25. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2019.06.002↗
  26. Cytopathological results of initial endoscopic ultrasound-guided fine needle aspiration for primary mass and prognosis in pancreatic cancer patients. Last author DOI 10.1111/cyt.12675↗
  27. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Sam… Co-author DOI 10.3389/fonc.2019.00875↗
  28. Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuva… Co-author DOI 10.5009/gnl18355↗
  29. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospect… Co-author DOI 10.1097/sla.0000000000002705↗
  30. Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. First author DOI 10.1177/1533033818783879↗
  31. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1373/clinchem.2017.283721↗
  32. Correction: Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Co-author DOI 10.18632/oncotarget.24175↗
  33. Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction c… Co-author DOI 10.3857/roj.2018.00073↗
  34. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine fo… Last author DOI 10.4143/crt.2016.495↗
  35. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Last author DOI 10.1016/j.pan.2016.09.001↗
  36. Development and Validation of a Prediction Model to Estimate Individual Risk of Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0146473↗
  37. Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. First author DOI 10.1186/1748-717x-8-160↗
  38. Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case-control study. Co-author DOI 10.3346/jkms.2013.28.2.247↗
  39. Endoscopic ultrasound elastography for pancreatic cancer diagnosis: a step forward? Co-author DOI 10.5946/ce.2013.46.2.116↗
  40. Changes in dietary intake, body weight, nutritional status, and metabolic rate in a pancreatic cancer patient. Co-author DOI 10.7762/cnr.2013.2.2.154↗
  41. Multiple primary malignant neoplasms in pancreatic cancer patients: a single-center experience in Korea. Co-author DOI 10.1097/mpa.0b013e3182374d65↗
  42. CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2010.10.011↗
  43. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and u… First author DOI 10.1016/j.ijrobp.2011.02.063↗

Closest collaborators

The 25 strongest of 121 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sang Myung Woo · 31 shared papers, 2011–2026 · strength 3.76
  2. Jung Won Chun · 11 shared papers, 2022–2026 · strength 2.43
  3. Sang‐Jae Park · 23 shared papers, 2011–2025 · strength 2.02
  4. Sung‐Sik Han · 20 shared papers, 2011–2026 · strength 1.97
  5. Sun‐Young Kong · 10 shared papers, 2017–2026 · strength 1.55
  6. Yun‐Hee Kim · 10 shared papers, 2016–2025 · strength 1.30
  7. Tae Hyun Kim · 13 shared papers, 2011–2025 · strength 0.93
  8. Jin‐Hyeok Hwang · 5 shared papers, 2019–2025 · strength 0.76
  9. Min Kyeong Kim · 6 shared papers, 2017–2025 · strength 0.73
  10. Yong‐Tae Kim · 4 shared papers, 2022–2025 · strength 0.67
  11. Kyong‐Ah Yoon · 6 shared papers, 2017–2024 · strength 0.61
  12. Sang Hyub Lee · 3 shared papers, 2022–2025 · strength 0.56
  13. Eui Joo Kim · 3 shared papers, 2024–2025 · strength 0.55
  14. Jin Seok Heo · 6 shared papers, 2018–2023 · strength 0.52
  15. Jin‐Young Jang · 6 shared papers, 2018–2023 · strength 0.52
  16. Joon Oh Park · 6 shared papers, 2018–2023 · strength 0.52
  17. Wooil Kwon · 6 shared papers, 2018–2023 · strength 0.52
  18. Soo‐Youl Kim · 2 shared papers, 2025–2026 · strength 0.47
  19. Seungyeoun Lee · 5 shared papers, 2018–2023 · strength 0.46
  20. Junghyun Namkung · 5 shared papers, 2018–2023 · strength 0.46
  21. Taesung Park · 5 shared papers, 2018–2023 · strength 0.46
  22. Joo Kyung Park · 5 shared papers, 2018–2023 · strength 0.46
  23. Chang Moo Kang · 5 shared papers, 2018–2023 · strength 0.46
  24. Song Cheol Kim · 5 shared papers, 2018–2023 · strength 0.46
  25. Hyeong Min Park · 2 shared papers, 2025 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.